David F. McDermott

Associate Professor of Medicine
Medicine
Beth Israel Deaconess Medical Center
United States of America

Academician Haematology
Biography

Dr. McDermott is a medical oncologist and clinical investigator with a particular interest in therapies that enhance the immune response to cancer. He has contributed to the rational application of interleukin-2 and biochemotherapy for renal cell carcinoma and melanoma. He is Director of the Cytokine Working Group which has been a major innovator in the field of solid tumor immunotherapy. More recently, he has worked with anti-angiogenic agents and targeted therapeutics for these malignancies.  Board certified in Internal Medicine, Medical Oncology and Hematology, Dr. McDermott earned his medical degree from Weill Medical College of Cornell University, completed a residency in internal medicine and a Fellowship in hematology/oncology at Tufts/New England Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School and a member of the editorial board for the Journal of Clinical Oncology.

Research Intrest

Bone Marrow Transplantation; Hematologic Malignancies; Renal Cancer; Melanoma

List of Publications
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. European Urology. 2017 Apr 12.
Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M. Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunology Research. 2017 Jun 1;5(6):446-54.
Einstein DJ, DeSanto-Madeya S, Gregas M, Lynch J, McDermott DF, Buss MK. Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies. Journal of Oncology Practice. 2017 May 31:JOP-2016.